Managing the next pandemic: the role of nasal vaccine administration
European Pharmaceutical Review
AUGUST 30, 2022
Nasal delivery is non-invasive and provides a more targeted delivery than the systemic injectable approach, potentially offering a quicker response and reduced side effects. million by 2029, up from $122.287 million in 2021. These innovations can go a long way towards making nasal a viable route for vaccine development.
119 
Let's personalize your content